Compare Aurobindo Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs WOCKHARDT - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA WOCKHARDT AUROBINDO PHARMA/
WOCKHARDT
 
P/E (TTM) x 19.9 -102.9 - View Chart
P/BV x 4.3 2.3 189.0% View Chart
Dividend Yield % 0.2 0.0 14,441.6%  

Financials

 AUROBINDO PHARMA   WOCKHARDT
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
WOCKHARDT
Mar-18
AUROBINDO PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs8301,012 82.0%   
Low Rs527532 99.2%   
Sales per share (Unadj.) Rs333.9355.9 93.8%  
Earnings per share (Unadj.) Rs40.4-60.3 -67.0%  
Cash flow per share (Unadj.) Rs51.8-46.8 -110.7%  
Dividends per share (Unadj.) Rs2.500.01 25,000.0%  
Dividend yield (eoy) %0.40 28,433.8%  
Book value per share (Unadj.) Rs237.1257.8 92.0%  
Shares outstanding (eoy) m585.91110.63 529.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.02.2 93.7%   
Avg P/E ratio x16.8-12.8 -131.3%  
P/CF ratio (eoy) x13.1-16.5 -79.4%  
Price / Book Value ratio x2.93.0 95.6%  
Dividend payout %6.20 -37,341.1%   
Avg Mkt Cap Rs m397,56985,379 465.7%   
No. of employees `00017.96.3 285.5%   
Total wages/salary Rs m25,8499,371 275.8%   
Avg. sales/employee Rs Th10,956.96,295.0 174.1%   
Avg. wages/employee Rs Th1,447.71,498.3 96.6%   
Avg. net profit/employee Rs Th1,324.3-1,066.3 -124.2%   
INCOME DATA
Net Sales Rs m195,63639,369 496.9%  
Other income Rs m1,5531,202 129.2%   
Total revenues Rs m197,18940,571 486.0%   
Gross profit Rs m39,51918 215,953.0%  
Depreciation Rs m6,6801,495 446.7%   
Interest Rs m2,6262,555 102.8%   
Profit before tax Rs m31,767-2,830 -1,122.7%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-3,582 24.6%   
Tax Rs m7,269257 2,828.2%   
Profit after tax Rs m23,645-6,669 -354.6%  
Gross profit margin %20.20 43,457.6%  
Effective tax rate %22.9-9.1 -251.9%   
Net profit margin %12.1-16.9 -71.4%  
BALANCE SHEET DATA
Current assets Rs m153,64533,796 454.6%   
Current liabilities Rs m120,42926,917 447.4%   
Net working cap to sales %17.017.5 97.2%  
Current ratio x1.31.3 101.6%  
Inventory Days Days13579 170.4%  
Debtors Days Days6489 71.4%  
Net fixed assets Rs m103,90939,664 262.0%   
Share capital Rs m586553 105.9%   
"Free" reserves Rs m138,32227,968 494.6%   
Net worth Rs m138,90828,522 487.0%   
Long term debt Rs m1,80021,731 8.3%   
Total assets Rs m264,54481,620 324.1%  
Interest coverage x13.1-0.1 -12,181.2%   
Debt to equity ratio x00.8 1.7%  
Sales to assets ratio x0.70.5 153.3%   
Return on assets %9.9-5.0 -197.0%  
Return on equity %17.0-23.4 -72.8%  
Return on capital %23.8-7.7 -310.6%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,3169,807 992.3%   
Fx outflow Rs m40,5891,789 2,269.3%   
Net fx Rs m56,7278,019 707.5%   
CASH FLOW
From Operations Rs m16,220684 2,370.0%  
From Investments Rs m-28,7686,302 -456.5%  
From Financial Activity Rs m19,191-7,695 -249.4%  
Net Cashflow Rs m6,656-664 -1,002.5%  

Share Holding

Indian Promoters % 54.1 74.5 72.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.3 345.7%  
FIIs % 27.7 7.7 359.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 67,757 102.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 200 Points Lower, Dow Futures Down by 59 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 240 points, down 0.5% at 49,262 levels.

Related Views on News

SUN PHARMA at 52 Week High; BSE 500 Index Down 0.5% (Market Updates)

May 11, 2021 | Updated on May 11, 2021

SUN PHARMA share price has hit a 52-week high. It is presently trading at Rs 721. BSE 500 Index is down by 0.5% at 20,096. Within the BSE 500, SUN PHARMA (up 3.2%) and CHENNAI PETROLEUM (up 7.1%) are among the top gainers, while top losers are INTELLECT DESIGN and SAIL.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 11, 2021 01:21 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS